澳至尊(02031.HK)完成配售1200萬股並恢復公眾持股量 明日復牌
格隆匯2月26日丨澳至尊(02031.HK)宣佈,該等認購協議項下所有條件已經達成,認購事項於2020年2月26日交割。公司按每股0.4港元,向該等認購人配發及發行合共1200萬股認購股份(即第一認購人獲325萬股認購股份,第二認購人獲500萬股認購股份及第三認購人獲375萬股認購股份)。
緊隨認購事項交割後,公眾人士持有合共1.995億股股份,佔公司全部已發行股本約26.18%。因此,認購事項交割後,公司的公眾持股量已恢復至不少於公司已發行股本的25%,符合上市規則第8.08(1)(a)條規定。
此外,公司已向聯交所申請股份於2020年2月27日(星期四)上午九時正起在聯交所恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.